Lords Mark Industries Limited (501261) — Announcement | 23 September 2026

Lord's Mark Industries announced its Technical Committee approved the final clinical trial stage for an AI-powered radiation-free breast cancer screening device, targeting regulatory clearances and commercial launch by April 2027. The technology, developed with C-MET, aims to detect cancer cell-level abnormalities with 98% accuracy across India, the USA, Europe, and Great Britain. Phase 2 trials begin January 2027, with CDSCO approval in process and global regulatory pathways being pursued. The wearable device uses thermal sensors and AI to identify cancer-linked temperature patterns without radiation, potentially expanding access to screening in underserved areas. The company is pursuing inclusion in national screening programs and insurance coverage through IRDAI to improve affordability and adoption.